Multi‐institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors

Cancer ◽  
2016 ◽  
Vol 123 (4) ◽  
pp. 688-696 ◽  
Author(s):  
Vivek Verma ◽  
Valerie K. Shostrom ◽  
Sameera S. Kumar ◽  
Weining Zhen ◽  
Christopher L. Hallemeier ◽  
...  
Keyword(s):  
Stereotactic Body Radiotherapy ◽  
Lung Tumors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Institutional Experience

EPID-based in vivo dosimetry for stereotactic body radiotherapy of non-small cell lung tumors: Initial clinical experience

2017 ◽  
Vol 42 ◽  
pp. 157-161 ◽  
Author(s):  
R. Consorti ◽  
A. Fidanzio ◽  
V. Brainovich ◽  
F. Mangiacotti ◽  
M. De Spirito ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Stereotactic Body Radiotherapy ◽  
Lung Tumors ◽  
Small Cell ◽  
In Vivo Dosimetry ◽  
Small Cell Lung ◽  
Initial Clinical Experience

scholarly journals Comparison of Oncologic Outcomes between Carbon Ion Radiotherapy and Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 176
Author(s):  
Yuhei Miyasaka ◽  
Shuichiro Komatsu ◽  
Takanori Abe ◽  
Nobuteru Kubo ◽  
Naoko Okano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Propensity Score ◽  
Small Cell Lung Cancer ◽  
Stereotactic Body Radiotherapy ◽  
Early Stage ◽  
Small Cell ◽  
Oncologic Outcomes ◽  
Comparison Study ◽  
Small Cell Lung ◽  
Early Stage Nsclc

Lung cancer is a leading cause of cancer-related deaths worldwide. Radiotherapy is an essential treatment modality for inoperable non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is the standard treatment for early-stage NSCLC because of its favorable local control (LC) compared to conventional radiotherapy. Carbon ion radiotherapy (CIRT) is a kind of external beam radiotherapy characterized by a steeper dose distribution and higher biological effectiveness. Several prospective studies have shown favorable outcomes. However, there is no direct comparison study between CIRT and SBRT to determine their benefits in the management of early-stage NSCLC. Thus, we conducted a retrospective, single-institutional, and contemporaneous comparison study, including propensity score-adjusted analyses, to clarify the differences in oncologic outcomes. The 3-year overall survival (OS) was 80.1% in CIRT and 71.6% in SBRT (p = 0.0077). The 3-year LC was 87.7% in the CIRT group and 79.1% in the SBRT group (p = 0.037). Multivariable analyses showed favorable OS and LC in the CIRT group (hazard risk [HR] = 0.41, p = 0.047; HR = 0.30, p = 0.040, respectively). Log-rank tests after propensity score matching and Cox regression analyses using propensity score confirmed these results. These data provided a positive efficacy profile of CIRT for early-stage NSCLC.

Sign in / Sign up

Export Citation Format

Share Document